Athira Pharma Inc, a Phase 2/3 neurodegeneration therapies developer, has filed Form S-1 Registration Statement on September 14, 2020 with U.S Securities and Exchange Commission to announce terms for its IPO.
The company plans to raise $160 million by offering 10 million shares at the price range of $15 to $17. Assuming a successful IPO at the midpoint of the proposed range, the company expects a market capitalization of $480 million.
The company focus on developing small molecule therapies to restore neuronal health and stop neurodegeneration. They aim to restore neuronal health for neurological disease patients, including Alzheimer’s disease, so that patients can regain their memories, lives, and family relationships.
The Seattle, Washington-based company was founded in 2011. It plans to list on the Nasdaq Global Market under the symbol “ATHA.” Goldman Sachs, Jefferies and Stifel are underwriters of the IPO.
The company engages Wilson Sonsini Goodrich & Rosati and Dorr LLP as US Securities Counsel, and Ernst & Young LLP as Independent Auditor.
#ipo #nasdaq #EY #therapies #biotech #neurodegeneration
Hexcellence Consulting has experienced IPO consulting team focus on listing in US Stock Market,
namely NYSE, Nasdaq and OTC Markets.
Should you interested to list your company in US Stock Market,
please contact us at [email protected].
